Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.38% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTVanda Pharmaceuticals Inc.'s latest supported as-filed period reports revenue of $50.5M, 3.9% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.38% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -61.49% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -3.92% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 3.32% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -126.28% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 73.13% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -31.0% from the comparable as-filed period.
Inventory changed -22.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Net income changed -129.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
VNDA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-053855SEC ↗8-KAug 5, 2026Period Aug 5, 20260001628280-26-053308SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261871SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261811SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261806SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261800SEC ↗4Jun 8, 2026Period Jun 4, 20260001193125-26-261790SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 4, 2026Filed Jun 8, 2026 | McGuire Daniel PatrickSVP, GC and Secretary | Grant Or AwardDirect | 80,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 4.17% · OPTIONAL
Operating income changed -65.7% from the comparable as-filed period.
Operating margin changed -5307 basis points from the comparable as-filed period.
Research & development changed +68.0% from the comparable as-filed period.
Revenue changed -3.9% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-261782